NCT02302066View on ClinicalTrials.gov

Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

1,800

Participants

Timeline

Start Date

December 5, 2014

Primary Completion Date

February 18, 2019

Study Completion Date

February 18, 2019

Conditions
Dengue Fever
Interventions
BIOLOGICAL

Takeda's Tetravalent Dengue Vaccine Candidate (TDV)

TDV subcutaneous injection

BIOLOGICAL

TDV Placebo

Placebo-matching vaccine

Trial Locations (3)

4114

Dela Salle Health Sciences Institute, Dasmariñas

10204

Hospital Maternidad Nuestra Senora de la Altagracia, Santo Domingo

10662

Centro De Vacunacion Internacional, S.A.(CEVAXIN), Panama City

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT02302066 - Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants | Biotech Hunter | Biotech Hunter